Synagis patent dispute ruling
Executive Summary
Federal appeals court affirms dismissal of MedImmune's declaratory judgment action relating to a Centocor patent it licenses for the respiratory syncytial virus treatment Synagis. MedImmune sought a declaration that it owes Centocor no royalties under the license agreement and that the patent is invalid or unenforceable. Court says MedImmune faced no "reasonable apprehension" that Centocor would sue for infringement...